Clinical syndromes and treatment location predict utility of carbapenem sparing therapies in ceftriaxone-non-susceptible Escherichia coli bloodstream infection

Cefiderocol, ceftazidime-avibactam, ceftolozane-tazobactam, intravenous fosfomycin and plazomicin represent potential carbapenem sparing agents for extended-spectrum-beta-lactamase or AmpC beta-lactamase produ...

Source: Annals of Clinical Microbiology and Antimicrobials - November 30, 2020 Category: Microbiology Authors: Ouli Xie, Kathryn Cisera, Lucy Taylor, Carly Hughes and Benjamin Rogers Tags: Research Source Type: research